ONL Therapeutics to Present at International Congresses
ONL Therapeutics, Inc., a pioneering biopharmaceutical company, has exciting news! The company will deliver podium presentations at two significant upcoming events: EYENOVATE and the FLORetina-ICOOR Congress. These noteworthy conferences will take place in December this year, bringing together experts from around the globe to discuss advances in retinal disease therapies.
Overview of the Presentations
At EYENOVATE, which debuts on December 4, ONL will showcase the presentation titled "Fas Inhibition with Xelafaslatide: A Novel Approach for the Treatment of Geographic Atrophy." This innovative research is set to be presented by Dr. David N. Zacks, the Chief Scientific Officer at ONL Therapeutics.
Presentation Details at EYENOVATE
This session is entitled "We Are in the Midst of a New Treatment Category: Dry AMD Innovation Update." It will take place at 9:45 AM Central European Time. The venue for this groundbreaking event will be the Fortezza da Basso in Florence, the heart of Italy.
Highlights of the FLORetina-ICOOR Presentation
Following EYENOVATE, ONL will also present its research during the FLORetina-ICOOR Congress from December 4-7. The second presentation is titled "Advancing Geographic Atrophy Treatment with ONL1204 (xelafaslatide): Insights from the Phase 1b Study and Phase 2 Launch." Dr. Baruch D. Kuppermann, a leading expert from the University of California, Irvine, will take the stage as a presenter.
Session Information for FLORetina-ICOOR
This presentation falls under the session "Retina Futura: Highlights in Geographic Atrophy (GA): Current Clinical Updates and Emerging Therapies." Scheduled on December 6, attendees can catch this insightful session at 4:15 PM CET, with ONL's presentation slot at 4:29 PM.
Engagement Opportunities
ONL Therapeutics will provide a booth at both conferences to engage with attendees, specifically for discussions related to the global Phase 2 GALAXY clinical trial. This trial assesses the effectiveness and safety of xelafaslatide in treating geographic atrophy associated with dry age-related macular degeneration.
Insight into Xelafaslatide
Xelafaslatide (ONL1204) works as a revolutionary small molecule Fas inhibitor aimed at safeguarding critical retinal cells from damaging processes that lead to vision loss. As an investigational therapy, it plays a vital role in mitigating photoreceptor cell death stemming from various retinal diseases. The later-stage clinical program for xelafaslatide involves multiple clinical trials, focusing on treatments related to geographic atrophy and retinal detachment.
Understanding Geographic Atrophy and AMD
Age-related macular degeneration (AMD) leads to significant visual impairment, affecting millions worldwide. Notably, geographic atrophy is an advanced form of AMD that severely impacts central vision and can lead to legal blindness. Various risk factors contribute to its incidence, including aging, lifestyle choices, and genetic predispositions. Therefore, continuous innovation in treatment is crucial.
About ONL Therapeutics
ONL Therapeutics is dedicated to developing groundbreaking therapeutics that enhance the quality of life for individuals suffering from retinal diseases. With a strong focus on innovative solutions to protect retinal cells from apoptosis mediated by fatal pathways, ONL Therapeutics stands at the forefront of vision-saving technology.
For further information about ONL Therapeutics, feel free to reach out:
Company Contact: Linda Kemnitz ONL Therapeutics, Inc. lkemnitz@onltherapeutics.com
Frequently Asked Questions
What events will ONL Therapeutics present at?
ONL Therapeutics will present at EYENOVATE and the FLORetina-ICOOR Congress.
Who is presenting the research on xelafaslatide?
Dr. David N. Zacks will present at EYENOVATE, while Dr. Baruch D. Kuppermann will present at FLORetina-ICOOR.
What is xelafaslatide used for?
Xelafaslatide is being researched for its effectiveness in treating geographic atrophy associated with age-related macular degeneration.
Where is the EYENOVATE conference being held?
EYENOVATE will take place at the Fortezza da Basso in Florence, Italy.
Who can attendees expect to meet at the ONL booth?
Attendees can meet representatives from clinical sites involved in ONL's global Phase 2 GALAXY clinical trial.
